Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.

Short telomeres (<4.17 kb) predict poorer progression-free survival in 917 treatment-naïve CLL patients receiving venetoclax-based regimens across multiple trials.

• Why it matters: Understanding prognostic factors under targeted therapies like venetoclax is crucial for improving risk stratification and personalized treatment in CLL, where traditional markers may not fully predict outcomes.
• What they did: Researchers measured telomere length using qPCR in samples from CLL patients enrolled in GAIA/CLL13 and CLL2-GIVe trials, analyzing associations with clinical features, genetic mutations, and survival outcomes.
• The result: Short telomeres were linked to adverse clinical and genetic features and independently predicted shorter progression-free survival, highlighting telomere length as a valuable prognostic marker in modern CLL therapy.